corvalol farmak tablets
pjsc "farmak" - alfa-bromisovaleric acid ethyl ester, phenobarbital, peppermint oil - tablets - 12.42mg+ 11.34mg+ 0.88mg
corvalol-pharmstandard drops oral
pharmstandard-leksredstva jsc - alfa-bromisovaleric acid ethyl ester, phenobarbital, peppermint oil - drops oral - 20mg/ml+ 18,26mg/ml+ 1,42mg/ml
corvalol-pharmstandard drops oral
pharmstandard-leksredstva jsc - alfa-bromisovaleric acid ethyl ester, phenobarbital, peppermint oil - drops oral - 20mg/ml+ 18,26mg/ml+ 1,42mg/ml
corsiz tablets
aversi-rational ltd - alfa-bromisovaleric acid ethyl ester, phenobarbital, peppermint oil - tablets - 8,2mg+ 7,5mg+ 0,58mg
corvalol-mff
moscow pharmaceutical factory jsc - alfa-bromisovaleric acid ethyl ester, phenobarbital - drops oral - 20mg/ml+18,26mg/ml
sucralfate- sucralfate tablet
pd-rx pharmaceuticals, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate tablet
northwind pharmaceuticals, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate oral suspension
pharmaceutical associates, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate suspension
physicians total care, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. there are no known contraindications to the use of sucralfate.
sucralfate suspension
precision dose inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.